Bio­gen vet jumps to CSO at Third Rock Treg biotech; Karuna CEO is step­ping down, but this is­n't good­bye

Just a few days in­to her new job, Ellen Cahir-Mc­Far­land’s of­fice is be­ing emp­tied.

Cahir-Mc­Far­land, for­mer­ly head of re­search at An­nex­on, is the new chief sci­en­tif­ic of­fi­cer of Aba­ta Ther­a­peu­tics, a pre­clin­i­cal biotech that’s de­vel­op­ing reg­u­la­to­ry T cell, or Treg, ther­a­pies for mul­ti­ple scle­ro­sis. On Mon­day, Aba­ta will be mov­ing from its cur­rent shared space to its new of­fice in Wa­ter­town, MA — hence the emp­ty­ing, Cahir-Mc­Far­land tells End­points News from a now bare, white-walled of­fice room.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER